-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sterling Bancorp, Inc. (SBT) on Behalf of Shareholders

SAN DIEGO & SOUTHFIELD, Mich.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Sterling Bancorp, Inc. (NASDAQ: SBT) breached their fiduciary duties to shareholders. Sterling Bancorp operates as the unitary thrift holding company for Sterling Bank and Trust, F.S.B.

If you suffered a loss as a result of Sterling Bancorp's misconduct, click here.

Sterling Bancorp, Inc. (SBT)'s Reported Results May Suffer Material Impact

On January 29, 2020, Sterling Bancorp issued a press release reporting its results of operation including net income of $56.9 million for fiscal year 2019 compared to net income of $63.5 million for fiscal year 2018. However, on March 17, 2020, Sterling Bancorp disclosed in its Form 10K filed with the SEC that due to its ongoing internal review relating to the termination of its Advantage Loan Program, the Company is unable to file its Form 10-K within the prescribed period of time as it may uncover information that "require[s] adjustments that would negatively impact the previously-announced results of operation." On this news, Sterling Bancorp's stock price declined 21% to close at $7.99 per share.

Sterling Bancorp, Inc. (SBT) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
LKandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leonid Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SBT

Release Versions
$Cashtags

Contacts

Leonid Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom